The observed alterations in clear cell carcinomas may be clinically relevant given that the Food and Drug Administration (FDA) has recently approved a PIK3CA inhibitor Piqray (alpelisib) combined with fulvestrant for the treatment of ER+/PIK3CA‐mutated metastatic breast carcinomas. This evidence concerns the gene PIK3CA and clear cell adenocarcinoma.